BETA
Your AI-Trained Oncology Knowledge Connection!
Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL
AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL
Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML
A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.
IDH Triplet Therapy Shows Excellent Outcomes in IDH-Mutant AML
Current data support prospective studies comparing IDH triplet vs IDH doublet therapies among patients with IDH-mutant acute myeloid leukemia.